Patents by Inventor Philip Jones

Philip Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230295173
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: March 13, 2023
    Publication date: September 21, 2023
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Timothy Joseph MCAFOOS
  • Publication number: 20230250081
    Abstract: Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: February 1, 2023
    Publication date: August 10, 2023
    Inventors: Philip JONES, Michael J. SOTH, Jason P. BURKE, Kang LE, Gang LIU
  • Publication number: 20230220501
    Abstract: Systems and a device for a pathogen detection system are described herein. For example, a pathogen detection system may include a pathogen detection device comprising an inlet, an outlet, and a reactive chamber; an imaging system comprising an excitation source and a fluorescence detection system; a substrate; and a heating element. In some examples, the pathogen detection system may be configured to detect one or more pathogens and/or viruses in a sample. For example, the pathogen detection device may receive a solution containing at least one of DNA or RNA and route the solution to the reactive chamber. Upon heating the solution, the pathogen detection device may further receive a probe containing one or more fluorescent dyes. The excitation source may excite the solution, and the detection system may detect an emission of the one or more fluorescent dyes.
    Type: Application
    Filed: January 11, 2023
    Publication date: July 13, 2023
    Inventors: Philip S. Measor, Kent Jones
  • Patent number: 11649859
    Abstract: A thin section bearing assembly is for a gantry assembly and includes inner and outer rings each having inner and outer circumferential surfaces and rolling elements grooves and are each sized such that a ratio of the inside diameter to radial thickness is at least thirty (30). A plurality of rolling elements, preferably balls, are disposed between the outer ring groove and the inner ring groove. At least one elastomeric annular damper is disposed between the outer ring and the housing and/or between the inner ring and the rotor and has first and second axially spaced sections. As such, the first section is compressed more than the second section under bending moments in a first angular direction and the second section is compressed more than the first section under moments in a second angular direction. The one or more annular dampers each have a thickness calculated to optimize vibration reduction.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: May 16, 2023
    Assignee: AKTIEBOLAGET SKF
    Inventors: Bryan Allison, Philip Jones, Joel Lawrence, Jason Williams
  • Publication number: 20230145868
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of the expression of miRNA, for use in the treatment or prevention of cancer.
    Type: Application
    Filed: December 22, 2022
    Publication date: May 11, 2023
    Inventors: George CALIN, Philip JONES, Barbara CZAKO, Simone ANFOSSI
  • Publication number: 20230124815
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: April 25, 2022
    Publication date: April 20, 2023
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Publication number: 20230109858
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: July 29, 2022
    Publication date: April 13, 2023
    Inventors: Philip JONES, Barbara CZAKO, Jason CROSS, Paul LEONARD, Faika MSEEH, Connor PARKER
  • Patent number: 11603365
    Abstract: Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: March 14, 2023
    Assignee: Board of Regents, the University of Texas System
    Inventors: Philip Jones, Michael J. Soth, Jason P. Burke, Kang Le, Gang Liu
  • Publication number: 20230027126
    Abstract: The present invention relates to ethanediamine-heterocycle compounds that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.
    Type: Application
    Filed: May 4, 2021
    Publication date: January 26, 2023
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy Joseph MCAFOOS
  • Patent number: 11560366
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: January 24, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael J. Soth, Kang Le, Philip Jones, Jason Cross
  • Publication number: 20230008047
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: May 21, 2021
    Publication date: January 12, 2023
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Christopher L. CARROLL, Timothy Joseph MCAFOOS, Pijus Kumar MANDAL
  • Patent number: 11535759
    Abstract: The present invention provides an anti-corrosion composition comprising an inorganic ion-exchanger and a waterborne resin, wherein a substrate exposed to a halide-containing environment and having the anti-corrosion composition applied thereto has a reduced level of corrosion compared to the substrate exposed to the halide-containing environment without the anti-corrosion composition being applied. The inventive waterborne anti-corrosion composition may find use on substrates such as automotive vehicles, bridges, cranes, superstructures, offshore oil & gas rigs, pipes, tanks, ships, barges, boats, aircraft, concrete, and masonry that are exposed to halide-containing environments.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: December 27, 2022
    Assignee: Covestro LLC
    Inventors: Makoto Nakao, Philip Jones, Carol Knox, Ilya Ilyin, Boris Tkachev
  • Publication number: 20220347201
    Abstract: Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.
    Type: Application
    Filed: June 27, 2022
    Publication date: November 3, 2022
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Michael A. CURRAN
  • Patent number: 11466017
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: October 11, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Philip Jones, Barbara Czako, Jason Cross, Paul Leonard, Faika Mseeh, Connor Parker
  • Publication number: 20220315652
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Application
    Filed: March 10, 2021
    Publication date: October 6, 2022
    Applicant: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • Patent number: 11439622
    Abstract: The present invention relates to certain compounds, in particular, indole derivatives that function as inhibitors of bacterial metallo-beta-lactamases. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of a bacterial infection.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: September 13, 2022
    Assignee: Oxford University Innovation Limited
    Inventors: J├╝rgen Brem, Anna M. Rydzik, Michael A. McDonough, Christopher J. Schofield, Angus Morrison, Joanne Hewitt, Andrew Pannifer, Philip Jones
  • Patent number: 11434233
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: September 6, 2022
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Suyambu Kesava Vijayan Ramaswamy, Michael Garrett Johnson, Sarah Lively, David Lapointe
  • Patent number: 11437957
    Abstract: A receiver is provided having a two-point-modulated phase-locked loop for the rapid scanning of the signal strength of a plurality of frequency channels. The two-point modulation includes a modulation of a frequency gain by an oscillator in the phase-locked loop and a modulation of a frequency division by a divider in the phase-locked loop.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: September 6, 2022
    Assignee: QUALCOMM Incorporated
    Inventors: Zafer Boz, Dhammika Bokolamulla, Philip Jones
  • Publication number: 20220267311
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Application
    Filed: March 10, 2022
    Publication date: August 25, 2022
    Inventors: Michael J. SOTH, Gang LIU, Kang LE, Jason CROSS, Philip JONES
  • Publication number: 20220259191
    Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.
    Type: Application
    Filed: September 22, 2021
    Publication date: August 18, 2022
    Inventors: Paolo PEVARELLO, William J. RAY, Mary HAMBY, Yaima Luzardo LIGHTFOOT, Philip JONES, Russell THOMAS, Chiara LIBERATI, Domenica TORINO, Valentina CUSANO, Francesco PISCITELLI, Ali Munaim YOUSIF, Silvia BOVOLENTA